MyFinsight

HomeBlogAboutContact

MyFinsight

Making company financials insightful for everyone

Quick Links

  • About
  • Blog
  • Contact

Follow Us

  • X.com
  • Thread
  • Instagram

© 2026 MyFinsight. All rights reserved.

|||

For the quarter ending 2025-09-30.

Income Overview

Net Income
-$9,291K
EPS
-$0.01
Unit: Thousand (K) dollars

Unit: Thousand (K) dollars (except for numbers of shares and EPS)
Income Statement
2025-09-30
2025-06-30
2025-03-31
2024-12-31
Revenue
0 500 --
Cost of revenue
0 132 --
Research and development
4,270 5,373 3,930 5,920
General and administrative
6,045 5,494 7,272 6,744
Other income
300 ---
Loss from operations
-10,015 -10,499 -11,202 -12,664
Interest income
504 589 659 686
Interest expense
28 24 180 339
Changes in the fair value of warrants
196 -101 416 -120
Foreign currency transaction (loss)/gain, net
1,873 -5,326 -2,765 2,545
Benefit from research and development tax credit
446 745 185 474
Net loss before income tax
-7,024 -14,616 -12,887 -9,417
Income tax benefit
0 0 --
Net loss
-7,024 -14,616 -12,887 -9,417
Other comprehensive income/(loss) - foreign currency translation adjustments, net of tax
-2,267 6,647 3,559 -2,846
Total comprehensive loss
-9,291 -7,969 -9,328 -12,263
Earnings per share, basic
-0.01 -0.02 -0.02 -0.013
Earnings per share, diluted
-0.01 -0.02 -0.02 -0.013
Weighted average number of shares outstanding, basic
799,947,013 799,435,329 784,279,387 -10,174,108.333
Weighted average number of shares outstanding, diluted
799,947,013 799,435,329 784,279,387 -10,174,108.333
Unit: Thousand (K) dollars (except for numbers of shares and EPS)

Time Plot

Show the time plot by selecting a row from the table.

Income Statement

DownloadDownload image
Total comprehensiveloss-$9,291K Other comprehensiveincome/(loss) - foreign...-$2,267K Net loss-$7,024K Net loss beforeincome tax-$7,024K Benefit from researchand development tax...$446K Foreign currencytransaction (loss)/gain,...$1,873K Changes in the fair valueof warrants$196K Interest income$504K Interest expense$28K Loss from operations-$10,015K Other income$300K General andadministrative$6,045K Research and development$4,270K

Mereo BioPharma Group plc (MREO)

Mereo BioPharma Group plc (MREO)